Is Vaxart Stock Really Worth a Shot?

53
5
Favorite

Is Vaxart Stock Really Worth a Shot?

InvestorPlace2021-08-31

If 10% of the population is refusing Covid-19 vaccine shots because they hate needles, that’s good news for VXRT stock. Biotech company Vaxart, Inc is like many others in this space. It’s a clinical-...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment（5）

JudLee
·2021-08-31
Can't wait for it to breakout again
Reply
Like
Report
KBchan
·2021-08-31
Please like and comment
Reply
1
Report
Fold Replies
- Singman:
  like too.
  2021-08-31
  Reply
  Report
HeatWave
·2021-08-31
Gogogog
Reply
2
Report
Fold Replies
- Cindypoonyw:
  Ok
  2021-08-31
  Reply
  Report
Kco
·2021-08-31
Yes!![Miser]
Reply
4
Report
Fold Replies
- Kco:
  [Miser][Miser]
  2021-08-31
  Reply
  Report
JamesArthur
·2021-08-31
Interesting
Reply
3
Report
Fold Replies
- HeatWave:
  yes
  2021-08-31
  Reply
  Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/1134243710?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2021-08-31 13:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1134243710","market":"us","top_or_hot":-1,"title":"Is Vaxart Stock Really Worth a Shot?","media":"InvestorPlace","content":"<div>\n<p>If 10% of the population is refusing Covid-19 vaccine shots because they hate needles, that’s good news for VXRT stock.\n\nBiotech company Vaxart, Inc is like many others in this space. It’s a clinical-...</p>\n\n<a href=\"https://investorplace.com/2021/08/is-vaxart-stock-really-worth-a-shot/\">Source Link</a>\n\n</div>\n","source":"lsy1606302653667","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Vaxart Stock Really Worth a Shot?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Vaxart Stock Really Worth a Shot?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-31 13:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/08/is-vaxart-stock-really-worth-a-shot/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>If 10% of the population is refusing Covid-19 vaccine shots because they hate needles, that’s good news for VXRT stock.\n\nBiotech company Vaxart, Inc is like many others in this space. It’s a clinical-...</p>\n\n<a href=\"https://investorplace.com/2021/08/is-vaxart-stock-really-worth-a-shot/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VXRT","symbol_name":"Vaxart, Inc","start_time":0,"source_url":"https://investorplace.com/2021/08/is-vaxart-stock-really-worth-a-shot/","article_id":"1134243710","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1134243710","pubTimestamp":1630388289,"sourceInfo":{"source_id":"lsy1606302653667","name":"InvestorPlace"},"weMediaInfo":null,"summary":"If 10% of the population is refusing Covid-19 vaccine shots because they hate needles, that’s good n","collect":0,"end_time":0,"defaultTopTitle":"investorplace.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"VXRT":"Vaxart, Inc"},"translate_title":"Vaxart股票真的值得一试吗？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VXRT":0.9},"content_text":"If 10% of the population is refusing Covid-19 vaccine shots because they hate needles, that’s good news for VXRT stock.\n\nBiotech company Vaxart, Inc is like many others in this space. It’s a clinical-stage company developing recombinant (rDNA) vaccines. It has a focus on Covid-19. And its stock has seen some wild, meme stock-style action in 2021, highlighted by a one-week period that saw VXRT stock spike 161% then plunge back below its starting point.\nWhat sets Vaxart apart from most of the biotech companies it competes with is syringes. More correctly, a lack of syringes. Instead of a needle, Vaxart’s vaccines are delivered in pill form.\nWhile VXRT stock experienced massive price fluctuations through the first 5 months of the year, since early May it has been stable with a recovery that is slowing gaining steam. Currently trading near $9, shares are up 40% from the start of the year. Vaxart hasn’t yet landed an approved Covid vaccine. But the Delta variant is proving that vaccination is likely to be an ongoing effort, meaning there is still opportunity there.\nVaxart has other oral vaccines in the pipeline including versions for norovirus and influenza. So is now the time to hop on the VXRT bandwagon?\nThere’s Vaccine Hesitancy, But There’s Also Needle Hesitancy\nOne of the central arguments to the Vaxart approach is that a lot of people strongly dislike needles. They can cause pain and extreme stress.\nDr. C. Meghan McMurtry is an associate professor of psychology at Canada’s University of Guelph. She wrote in theNew York Times: “About one in four adults and two out of three children have some fear of needles, and adults may find their fears too shameful to share. This is a substantial public health problem, because a body of research shows that around one in 10 adults are so afraid of needles that they will delay or avoid vaccinations.”\nDelaying or avoiding vaccination is prolonging the pandemic. Not all vaccine refusers are avoiding the shot because they fear needles. But a substantial number are. And with children under 12 the next big age group that remains to be vaccinated in the U.S., fear of needles is a serious issue.\nEven once the pandemic is under control, it appears that mutations like Delta will mean ongoing booster shots are required. Fear of needles will be a problem for the foreseeable issue.\nThat is a huge opportunity for Vaxart. Success with its oral Covid-19 vaccine — which recently received Food and Drug Administration approval to begin phase II clinical trials— would be a huge catalyst for VXRT stock.\nOral Vaccines Have a Practical Application As Well\nCatering to a group that avoids needles is one thing. However, there are also a practical reasons for developing an oral Covid-19 vaccine.\nThe Covid-19 vaccines released to date have had very stringent temperature requirements for transportation and storage, some requiring specialized freezers. That was a challenge at first in parts of North America, but in areas of the world like Africa where temperatures are extreme and infrastructure often lacking, this becomes a big problem. In addition, there have been shortages of syringes and of people trained to administer needles.\nWith an oral vaccination — a pill — these issues go away. Vaxart says its tablets are stable at room temperature, eliminating the challenges with transportation and storage. In addition, there is no special equipment or specialized training needed at clinics where the pills would be distributed.\nBottom Line on VXRT Stock\nWill Vaxart achieve the Holy Grail of a pill-based rDNA vaccine for Covid-19? If the company manages to pull it off, early February’s $23.33 close will likely end up looking like a practice run for VXRT stock. With the vaccine candidate just scheduled to enter phase II clinical trials in the second half of the year, patience is required.\nThisPortfolio GraderB-rated stock is not without risk. Vaccine candidates fail during testing all the time, and underwhelming phase I trial results sank VXRT in February. However, its stock price has stabilized and is trending in the right direction. And in its latest quarter, Vaxart reported it still has$198.9 million in cash and equivalents to keep the lights on while it waits for its oral Covid-19 vaccine to work its way through clinical trials.\nRemember, even if the company doesn’t succeed on the Covid-19 front, the company has other oral vaccine candidates in various stages of development in the pipeline.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":818545915,"gmtCreate":1630421957437,"gmtModify":1676530300100,"author":{"id":"3577759236192678","authorId":"3577759236192678","authorIdStr":"3577759236192678","name":"JudLee","avatar":"https://static.tigerbbs.com/839d5ec5e5f0826f3a6d5f19ec16ee58","vip":1,"crmLevel":5,"crmLevelSwitch":1,"idStr":"3577759236192678"},"htmlText":"Can't wait for it to breakout again","listText":"Can't wait for it to breakout again","text":"Can't wait for it to breakout again","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/818545915","repostId":1134243710,"repostType":2,"repost":{"id":"1134243710","pubTimestamp":1630388289,"share":"https://ttm.financial/m/news/1134243710?lang=&edition=fundamental","pubTime":"2021-08-31 13:38","market":"us","language":"en","title":"Is Vaxart Stock Really Worth a Shot?","url":"https://stock-news.laohu8.com/highlight/detail?id=1134243710","media":"InvestorPlace","summary":"If 10% of the population is refusing Covid-19 vaccine shots because they hate needles, that’s good n","content":"<blockquote>\n <b>If 10% of the population is refusing Covid-19 vaccine shots because they hate needles, that’s good news for VXRT stock.</b>\n</blockquote>\n<p>Biotech company&nbsp;<b><a href=\"https://laohu8.com/S/VXRT\">Vaxart, Inc</a></b> is like many others in this space. It’s a clinical-stage company developing recombinant (rDNA) vaccines. It has a focus on Covid-19. And its stock has seen some wild, meme stock-style action in 2021, highlighted by a one-week period that saw VXRT stock spike 161% then plunge back below its starting point.</p>\n<p>What sets Vaxart apart from most of the biotech companies it competes with is syringes. More correctly, a lack of syringes. Instead of a needle, Vaxart’s vaccines are delivered in pill form.</p>\n<p>While VXRT stock experienced massive price fluctuations through the first 5 months of the year, since early May it has been stable with a recovery that is slowing gaining steam. Currently trading near $9, shares are up 40% from the start of the year. Vaxart hasn’t yet landed an approved Covid vaccine. But the Delta variant is proving that vaccination is likely to be an ongoing effort, meaning there is still opportunity there.</p>\n<p>Vaxart has other oral vaccines in the pipeline including versions for norovirus and influenza. So is now the time to hop on the VXRT bandwagon?</p>\n<p><b>There’s Vaccine Hesitancy, But There’s Also Needle Hesitancy</b></p>\n<p>One of the central arguments to the Vaxart approach is that a lot of people strongly dislike needles. They can cause pain and extreme stress.</p>\n<p>Dr. C. Meghan McMurtry is an associate professor of psychology at Canada’s University of Guelph.&nbsp;She wrote in the<i>New York Times</i>: “About one in four adults and two out of three children have some fear of needles, and adults may find their fears too shameful to share. This is a substantial public health problem, because a body of research shows that around one in 10 adults are so afraid of needles that they will delay or avoid vaccinations.”</p>\n<p>Delaying or avoiding vaccination is&nbsp;prolonging the pandemic. Not all vaccine refusers are avoiding the shot because they fear needles. But a substantial number are. And with children under 12 the next big age group that remains to be vaccinated in the U.S., fear of needles is a serious issue.</p>\n<p>Even once the pandemic is under control, it appears that mutations like Delta will mean ongoing&nbsp;booster shots are required. Fear of needles will be a problem for the foreseeable issue.</p>\n<p>That is a huge opportunity for Vaxart. Success with its oral Covid-19 vaccine — which recently&nbsp;received Food and Drug Administration approval to begin phase II clinical trials—&nbsp;would be a&nbsp;huge catalyst for VXRT stock.</p>\n<p><b>Oral Vaccines Have a Practical Application As Well</b></p>\n<p>Catering to a group that avoids needles is one thing. However, there are also a practical reasons for developing an oral Covid-19 vaccine.</p>\n<p>The Covid-19 vaccines released to date have had very stringent temperature requirements for transportation and storage, some requiring specialized freezers. That was a challenge at first in parts of North America, but in areas of the world like Africa where temperatures are extreme and infrastructure often lacking, this becomes a big problem. In addition, there have been&nbsp;shortages of syringes&nbsp;and of people trained to administer needles.</p>\n<p>With an oral vaccination — a pill — these issues go away. Vaxart says its tablets are stable at room temperature, eliminating the challenges with transportation and storage. In addition, there is no special equipment or specialized training needed at clinics where the pills would be distributed.</p>\n<p><b>Bottom Line on VXRT Stock</b></p>\n<p>Will Vaxart achieve the Holy Grail of a pill-based rDNA vaccine for Covid-19? If the company manages to pull it off, early February’s $23.33 close will likely end up looking like a practice run for VXRT stock. With the vaccine candidate just scheduled to enter phase II clinical trials in the second half of the year, patience is required.</p>\n<p>This<i>Portfolio Grader</i>B-rated stock is not without risk. Vaccine candidates fail during testing all the time, and underwhelming phase I trial results sank VXRT in February. However, its stock price has stabilized and is trending in the right direction. And in its latest quarter, Vaxart reported it still has$198.9 million in cash and equivalents&nbsp;to keep the lights on while it waits for its oral Covid-19 vaccine to work its way through clinical trials.</p>\n<p>Remember, even if the company doesn’t succeed on the Covid-19 front, the company has other oral vaccine candidates in various stages of development in the pipeline.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Vaxart Stock Really Worth a Shot?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Vaxart Stock Really Worth a Shot?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-31 13:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/08/is-vaxart-stock-really-worth-a-shot/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>If 10% of the population is refusing Covid-19 vaccine shots because they hate needles, that’s good news for VXRT stock.\n\nBiotech company Vaxart, Inc is like many others in this space. It’s a clinical-...</p>\n\n<a href=\"https://investorplace.com/2021/08/is-vaxart-stock-really-worth-a-shot/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VXRT":"Vaxart, Inc"},"source_url":"https://investorplace.com/2021/08/is-vaxart-stock-really-worth-a-shot/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1134243710","content_text":"If 10% of the population is refusing Covid-19 vaccine shots because they hate needles, that’s good news for VXRT stock.\n\nBiotech company Vaxart, Inc is like many others in this space. It’s a clinical-stage company developing recombinant (rDNA) vaccines. It has a focus on Covid-19. And its stock has seen some wild, meme stock-style action in 2021, highlighted by a one-week period that saw VXRT stock spike 161% then plunge back below its starting point.\nWhat sets Vaxart apart from most of the biotech companies it competes with is syringes. More correctly, a lack of syringes. Instead of a needle, Vaxart’s vaccines are delivered in pill form.\nWhile VXRT stock experienced massive price fluctuations through the first 5 months of the year, since early May it has been stable with a recovery that is slowing gaining steam. Currently trading near $9, shares are up 40% from the start of the year. Vaxart hasn’t yet landed an approved Covid vaccine. But the Delta variant is proving that vaccination is likely to be an ongoing effort, meaning there is still opportunity there.\nVaxart has other oral vaccines in the pipeline including versions for norovirus and influenza. So is now the time to hop on the VXRT bandwagon?\nThere’s Vaccine Hesitancy, But There’s Also Needle Hesitancy\nOne of the central arguments to the Vaxart approach is that a lot of people strongly dislike needles. They can cause pain and extreme stress.\nDr. C. Meghan McMurtry is an associate professor of psychology at Canada’s University of Guelph. She wrote in theNew York Times: “About one in four adults and two out of three children have some fear of needles, and adults may find their fears too shameful to share. This is a substantial public health problem, because a body of research shows that around one in 10 adults are so afraid of needles that they will delay or avoid vaccinations.”\nDelaying or avoiding vaccination is prolonging the pandemic. Not all vaccine refusers are avoiding the shot because they fear needles. But a substantial number are. And with children under 12 the next big age group that remains to be vaccinated in the U.S., fear of needles is a serious issue.\nEven once the pandemic is under control, it appears that mutations like Delta will mean ongoing booster shots are required. Fear of needles will be a problem for the foreseeable issue.\nThat is a huge opportunity for Vaxart. Success with its oral Covid-19 vaccine — which recently received Food and Drug Administration approval to begin phase II clinical trials— would be a huge catalyst for VXRT stock.\nOral Vaccines Have a Practical Application As Well\nCatering to a group that avoids needles is one thing. However, there are also a practical reasons for developing an oral Covid-19 vaccine.\nThe Covid-19 vaccines released to date have had very stringent temperature requirements for transportation and storage, some requiring specialized freezers. That was a challenge at first in parts of North America, but in areas of the world like Africa where temperatures are extreme and infrastructure often lacking, this becomes a big problem. In addition, there have been shortages of syringes and of people trained to administer needles.\nWith an oral vaccination — a pill — these issues go away. Vaxart says its tablets are stable at room temperature, eliminating the challenges with transportation and storage. In addition, there is no special equipment or specialized training needed at clinics where the pills would be distributed.\nBottom Line on VXRT Stock\nWill Vaxart achieve the Holy Grail of a pill-based rDNA vaccine for Covid-19? If the company manages to pull it off, early February’s $23.33 close will likely end up looking like a practice run for VXRT stock. With the vaccine candidate just scheduled to enter phase II clinical trials in the second half of the year, patience is required.\nThisPortfolio GraderB-rated stock is not without risk. Vaccine candidates fail during testing all the time, and underwhelming phase I trial results sank VXRT in February. However, its stock price has stabilized and is trending in the right direction. And in its latest quarter, Vaxart reported it still has$198.9 million in cash and equivalents to keep the lights on while it waits for its oral Covid-19 vaccine to work its way through clinical trials.\nRemember, even if the company doesn’t succeed on the Covid-19 front, the company has other oral vaccine candidates in various stages of development in the pipeline.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":818800776,"gmtCreate":1630390645795,"gmtModify":1676530289266,"author":{"id":"3582453112692311","authorId":"3582453112692311","authorIdStr":"3582453112692311","name":"KBchan","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3582453112692311"},"htmlText":"Please like and comment","listText":"Please like and comment","text":"Please like and comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/818800776","repostId":1134243710,"repostType":4,"repost":{"id":"1134243710","pubTimestamp":1630388289,"share":"https://ttm.financial/m/news/1134243710?lang=&edition=fundamental","pubTime":"2021-08-31 13:38","market":"us","language":"en","title":"Is Vaxart Stock Really Worth a Shot?","url":"https://stock-news.laohu8.com/highlight/detail?id=1134243710","media":"InvestorPlace","summary":"If 10% of the population is refusing Covid-19 vaccine shots because they hate needles, that’s good n","content":"<blockquote>\n <b>If 10% of the population is refusing Covid-19 vaccine shots because they hate needles, that’s good news for VXRT stock.</b>\n</blockquote>\n<p>Biotech company&nbsp;<b><a href=\"https://laohu8.com/S/VXRT\">Vaxart, Inc</a></b> is like many others in this space. It’s a clinical-stage company developing recombinant (rDNA) vaccines. It has a focus on Covid-19. And its stock has seen some wild, meme stock-style action in 2021, highlighted by a one-week period that saw VXRT stock spike 161% then plunge back below its starting point.</p>\n<p>What sets Vaxart apart from most of the biotech companies it competes with is syringes. More correctly, a lack of syringes. Instead of a needle, Vaxart’s vaccines are delivered in pill form.</p>\n<p>While VXRT stock experienced massive price fluctuations through the first 5 months of the year, since early May it has been stable with a recovery that is slowing gaining steam. Currently trading near $9, shares are up 40% from the start of the year. Vaxart hasn’t yet landed an approved Covid vaccine. But the Delta variant is proving that vaccination is likely to be an ongoing effort, meaning there is still opportunity there.</p>\n<p>Vaxart has other oral vaccines in the pipeline including versions for norovirus and influenza. So is now the time to hop on the VXRT bandwagon?</p>\n<p><b>There’s Vaccine Hesitancy, But There’s Also Needle Hesitancy</b></p>\n<p>One of the central arguments to the Vaxart approach is that a lot of people strongly dislike needles. They can cause pain and extreme stress.</p>\n<p>Dr. C. Meghan McMurtry is an associate professor of psychology at Canada’s University of Guelph.&nbsp;She wrote in the<i>New York Times</i>: “About one in four adults and two out of three children have some fear of needles, and adults may find their fears too shameful to share. This is a substantial public health problem, because a body of research shows that around one in 10 adults are so afraid of needles that they will delay or avoid vaccinations.”</p>\n<p>Delaying or avoiding vaccination is&nbsp;prolonging the pandemic. Not all vaccine refusers are avoiding the shot because they fear needles. But a substantial number are. And with children under 12 the next big age group that remains to be vaccinated in the U.S., fear of needles is a serious issue.</p>\n<p>Even once the pandemic is under control, it appears that mutations like Delta will mean ongoing&nbsp;booster shots are required. Fear of needles will be a problem for the foreseeable issue.</p>\n<p>That is a huge opportunity for Vaxart. Success with its oral Covid-19 vaccine — which recently&nbsp;received Food and Drug Administration approval to begin phase II clinical trials—&nbsp;would be a&nbsp;huge catalyst for VXRT stock.</p>\n<p><b>Oral Vaccines Have a Practical Application As Well</b></p>\n<p>Catering to a group that avoids needles is one thing. However, there are also a practical reasons for developing an oral Covid-19 vaccine.</p>\n<p>The Covid-19 vaccines released to date have had very stringent temperature requirements for transportation and storage, some requiring specialized freezers. That was a challenge at first in parts of North America, but in areas of the world like Africa where temperatures are extreme and infrastructure often lacking, this becomes a big problem. In addition, there have been&nbsp;shortages of syringes&nbsp;and of people trained to administer needles.</p>\n<p>With an oral vaccination — a pill — these issues go away. Vaxart says its tablets are stable at room temperature, eliminating the challenges with transportation and storage. In addition, there is no special equipment or specialized training needed at clinics where the pills would be distributed.</p>\n<p><b>Bottom Line on VXRT Stock</b></p>\n<p>Will Vaxart achieve the Holy Grail of a pill-based rDNA vaccine for Covid-19? If the company manages to pull it off, early February’s $23.33 close will likely end up looking like a practice run for VXRT stock. With the vaccine candidate just scheduled to enter phase II clinical trials in the second half of the year, patience is required.</p>\n<p>This<i>Portfolio Grader</i>B-rated stock is not without risk. Vaccine candidates fail during testing all the time, and underwhelming phase I trial results sank VXRT in February. However, its stock price has stabilized and is trending in the right direction. And in its latest quarter, Vaxart reported it still has$198.9 million in cash and equivalents&nbsp;to keep the lights on while it waits for its oral Covid-19 vaccine to work its way through clinical trials.</p>\n<p>Remember, even if the company doesn’t succeed on the Covid-19 front, the company has other oral vaccine candidates in various stages of development in the pipeline.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Vaxart Stock Really Worth a Shot?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Vaxart Stock Really Worth a Shot?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-31 13:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/08/is-vaxart-stock-really-worth-a-shot/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>If 10% of the population is refusing Covid-19 vaccine shots because they hate needles, that’s good news for VXRT stock.\n\nBiotech company Vaxart, Inc is like many others in this space. It’s a clinical-...</p>\n\n<a href=\"https://investorplace.com/2021/08/is-vaxart-stock-really-worth-a-shot/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VXRT":"Vaxart, Inc"},"source_url":"https://investorplace.com/2021/08/is-vaxart-stock-really-worth-a-shot/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1134243710","content_text":"If 10% of the population is refusing Covid-19 vaccine shots because they hate needles, that’s good news for VXRT stock.\n\nBiotech company Vaxart, Inc is like many others in this space. It’s a clinical-stage company developing recombinant (rDNA) vaccines. It has a focus on Covid-19. And its stock has seen some wild, meme stock-style action in 2021, highlighted by a one-week period that saw VXRT stock spike 161% then plunge back below its starting point.\nWhat sets Vaxart apart from most of the biotech companies it competes with is syringes. More correctly, a lack of syringes. Instead of a needle, Vaxart’s vaccines are delivered in pill form.\nWhile VXRT stock experienced massive price fluctuations through the first 5 months of the year, since early May it has been stable with a recovery that is slowing gaining steam. Currently trading near $9, shares are up 40% from the start of the year. Vaxart hasn’t yet landed an approved Covid vaccine. But the Delta variant is proving that vaccination is likely to be an ongoing effort, meaning there is still opportunity there.\nVaxart has other oral vaccines in the pipeline including versions for norovirus and influenza. So is now the time to hop on the VXRT bandwagon?\nThere’s Vaccine Hesitancy, But There’s Also Needle Hesitancy\nOne of the central arguments to the Vaxart approach is that a lot of people strongly dislike needles. They can cause pain and extreme stress.\nDr. C. Meghan McMurtry is an associate professor of psychology at Canada’s University of Guelph. She wrote in theNew York Times: “About one in four adults and two out of three children have some fear of needles, and adults may find their fears too shameful to share. This is a substantial public health problem, because a body of research shows that around one in 10 adults are so afraid of needles that they will delay or avoid vaccinations.”\nDelaying or avoiding vaccination is prolonging the pandemic. Not all vaccine refusers are avoiding the shot because they fear needles. But a substantial number are. And with children under 12 the next big age group that remains to be vaccinated in the U.S., fear of needles is a serious issue.\nEven once the pandemic is under control, it appears that mutations like Delta will mean ongoing booster shots are required. Fear of needles will be a problem for the foreseeable issue.\nThat is a huge opportunity for Vaxart. Success with its oral Covid-19 vaccine — which recently received Food and Drug Administration approval to begin phase II clinical trials— would be a huge catalyst for VXRT stock.\nOral Vaccines Have a Practical Application As Well\nCatering to a group that avoids needles is one thing. However, there are also a practical reasons for developing an oral Covid-19 vaccine.\nThe Covid-19 vaccines released to date have had very stringent temperature requirements for transportation and storage, some requiring specialized freezers. That was a challenge at first in parts of North America, but in areas of the world like Africa where temperatures are extreme and infrastructure often lacking, this becomes a big problem. In addition, there have been shortages of syringes and of people trained to administer needles.\nWith an oral vaccination — a pill — these issues go away. Vaxart says its tablets are stable at room temperature, eliminating the challenges with transportation and storage. In addition, there is no special equipment or specialized training needed at clinics where the pills would be distributed.\nBottom Line on VXRT Stock\nWill Vaxart achieve the Holy Grail of a pill-based rDNA vaccine for Covid-19? If the company manages to pull it off, early February’s $23.33 close will likely end up looking like a practice run for VXRT stock. With the vaccine candidate just scheduled to enter phase II clinical trials in the second half of the year, patience is required.\nThisPortfolio GraderB-rated stock is not without risk. Vaccine candidates fail during testing all the time, and underwhelming phase I trial results sank VXRT in February. However, its stock price has stabilized and is trending in the right direction. And in its latest quarter, Vaxart reported it still has$198.9 million in cash and equivalents to keep the lights on while it waits for its oral Covid-19 vaccine to work its way through clinical trials.\nRemember, even if the company doesn’t succeed on the Covid-19 front, the company has other oral vaccine candidates in various stages of development in the pipeline.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5703615,"gmtCreate":1630391770800,"gmtModify":1663233160125,"authorId":3575125836760247,"author":{"id":3575125836760247,"authorId":3575125836760247,"name":"Singman","avatar":"https://static.tigerbbs.com/d770feb757705f2d631d2d5f381ae07b","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":818800776,"type":1,"supId":0,"prevId":0,"content":"like too.","text":"like too.","html":"like too."}],"langContent":"EN"},{"id":818170952,"gmtCreate":1630389515176,"gmtModify":1676530288962,"author":{"id":"3581648699031335","authorId":"3581648699031335","authorIdStr":"3581648699031335","name":"HeatWave","avatar":"https://static.tigerbbs.com/df15a10254b322279c673072699eb4cf","vip":1,"hat":"https://static.tigerbbs.com/f84859c65fc2d7681e28f6b8e9b0535a","crmLevel":2,"crmLevelSwitch":0,"idStr":"3581648699031335"},"htmlText":"Gogogog","listText":"Gogogog","text":"Gogogog","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/818170952","repostId":1134243710,"repostType":4,"repost":{"id":"1134243710","pubTimestamp":1630388289,"share":"https://ttm.financial/m/news/1134243710?lang=&edition=fundamental","pubTime":"2021-08-31 13:38","market":"us","language":"en","title":"Is Vaxart Stock Really Worth a Shot?","url":"https://stock-news.laohu8.com/highlight/detail?id=1134243710","media":"InvestorPlace","summary":"If 10% of the population is refusing Covid-19 vaccine shots because they hate needles, that’s good n","content":"<blockquote>\n <b>If 10% of the population is refusing Covid-19 vaccine shots because they hate needles, that’s good news for VXRT stock.</b>\n</blockquote>\n<p>Biotech company&nbsp;<b><a href=\"https://laohu8.com/S/VXRT\">Vaxart, Inc</a></b> is like many others in this space. It’s a clinical-stage company developing recombinant (rDNA) vaccines. It has a focus on Covid-19. And its stock has seen some wild, meme stock-style action in 2021, highlighted by a one-week period that saw VXRT stock spike 161% then plunge back below its starting point.</p>\n<p>What sets Vaxart apart from most of the biotech companies it competes with is syringes. More correctly, a lack of syringes. Instead of a needle, Vaxart’s vaccines are delivered in pill form.</p>\n<p>While VXRT stock experienced massive price fluctuations through the first 5 months of the year, since early May it has been stable with a recovery that is slowing gaining steam. Currently trading near $9, shares are up 40% from the start of the year. Vaxart hasn’t yet landed an approved Covid vaccine. But the Delta variant is proving that vaccination is likely to be an ongoing effort, meaning there is still opportunity there.</p>\n<p>Vaxart has other oral vaccines in the pipeline including versions for norovirus and influenza. So is now the time to hop on the VXRT bandwagon?</p>\n<p><b>There’s Vaccine Hesitancy, But There’s Also Needle Hesitancy</b></p>\n<p>One of the central arguments to the Vaxart approach is that a lot of people strongly dislike needles. They can cause pain and extreme stress.</p>\n<p>Dr. C. Meghan McMurtry is an associate professor of psychology at Canada’s University of Guelph.&nbsp;She wrote in the<i>New York Times</i>: “About one in four adults and two out of three children have some fear of needles, and adults may find their fears too shameful to share. This is a substantial public health problem, because a body of research shows that around one in 10 adults are so afraid of needles that they will delay or avoid vaccinations.”</p>\n<p>Delaying or avoiding vaccination is&nbsp;prolonging the pandemic. Not all vaccine refusers are avoiding the shot because they fear needles. But a substantial number are. And with children under 12 the next big age group that remains to be vaccinated in the U.S., fear of needles is a serious issue.</p>\n<p>Even once the pandemic is under control, it appears that mutations like Delta will mean ongoing&nbsp;booster shots are required. Fear of needles will be a problem for the foreseeable issue.</p>\n<p>That is a huge opportunity for Vaxart. Success with its oral Covid-19 vaccine — which recently&nbsp;received Food and Drug Administration approval to begin phase II clinical trials—&nbsp;would be a&nbsp;huge catalyst for VXRT stock.</p>\n<p><b>Oral Vaccines Have a Practical Application As Well</b></p>\n<p>Catering to a group that avoids needles is one thing. However, there are also a practical reasons for developing an oral Covid-19 vaccine.</p>\n<p>The Covid-19 vaccines released to date have had very stringent temperature requirements for transportation and storage, some requiring specialized freezers. That was a challenge at first in parts of North America, but in areas of the world like Africa where temperatures are extreme and infrastructure often lacking, this becomes a big problem. In addition, there have been&nbsp;shortages of syringes&nbsp;and of people trained to administer needles.</p>\n<p>With an oral vaccination — a pill — these issues go away. Vaxart says its tablets are stable at room temperature, eliminating the challenges with transportation and storage. In addition, there is no special equipment or specialized training needed at clinics where the pills would be distributed.</p>\n<p><b>Bottom Line on VXRT Stock</b></p>\n<p>Will Vaxart achieve the Holy Grail of a pill-based rDNA vaccine for Covid-19? If the company manages to pull it off, early February’s $23.33 close will likely end up looking like a practice run for VXRT stock. With the vaccine candidate just scheduled to enter phase II clinical trials in the second half of the year, patience is required.</p>\n<p>This<i>Portfolio Grader</i>B-rated stock is not without risk. Vaccine candidates fail during testing all the time, and underwhelming phase I trial results sank VXRT in February. However, its stock price has stabilized and is trending in the right direction. And in its latest quarter, Vaxart reported it still has$198.9 million in cash and equivalents&nbsp;to keep the lights on while it waits for its oral Covid-19 vaccine to work its way through clinical trials.</p>\n<p>Remember, even if the company doesn’t succeed on the Covid-19 front, the company has other oral vaccine candidates in various stages of development in the pipeline.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Vaxart Stock Really Worth a Shot?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Vaxart Stock Really Worth a Shot?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-31 13:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/08/is-vaxart-stock-really-worth-a-shot/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>If 10% of the population is refusing Covid-19 vaccine shots because they hate needles, that’s good news for VXRT stock.\n\nBiotech company Vaxart, Inc is like many others in this space. It’s a clinical-...</p>\n\n<a href=\"https://investorplace.com/2021/08/is-vaxart-stock-really-worth-a-shot/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VXRT":"Vaxart, Inc"},"source_url":"https://investorplace.com/2021/08/is-vaxart-stock-really-worth-a-shot/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1134243710","content_text":"If 10% of the population is refusing Covid-19 vaccine shots because they hate needles, that’s good news for VXRT stock.\n\nBiotech company Vaxart, Inc is like many others in this space. It’s a clinical-stage company developing recombinant (rDNA) vaccines. It has a focus on Covid-19. And its stock has seen some wild, meme stock-style action in 2021, highlighted by a one-week period that saw VXRT stock spike 161% then plunge back below its starting point.\nWhat sets Vaxart apart from most of the biotech companies it competes with is syringes. More correctly, a lack of syringes. Instead of a needle, Vaxart’s vaccines are delivered in pill form.\nWhile VXRT stock experienced massive price fluctuations through the first 5 months of the year, since early May it has been stable with a recovery that is slowing gaining steam. Currently trading near $9, shares are up 40% from the start of the year. Vaxart hasn’t yet landed an approved Covid vaccine. But the Delta variant is proving that vaccination is likely to be an ongoing effort, meaning there is still opportunity there.\nVaxart has other oral vaccines in the pipeline including versions for norovirus and influenza. So is now the time to hop on the VXRT bandwagon?\nThere’s Vaccine Hesitancy, But There’s Also Needle Hesitancy\nOne of the central arguments to the Vaxart approach is that a lot of people strongly dislike needles. They can cause pain and extreme stress.\nDr. C. Meghan McMurtry is an associate professor of psychology at Canada’s University of Guelph. She wrote in theNew York Times: “About one in four adults and two out of three children have some fear of needles, and adults may find their fears too shameful to share. This is a substantial public health problem, because a body of research shows that around one in 10 adults are so afraid of needles that they will delay or avoid vaccinations.”\nDelaying or avoiding vaccination is prolonging the pandemic. Not all vaccine refusers are avoiding the shot because they fear needles. But a substantial number are. And with children under 12 the next big age group that remains to be vaccinated in the U.S., fear of needles is a serious issue.\nEven once the pandemic is under control, it appears that mutations like Delta will mean ongoing booster shots are required. Fear of needles will be a problem for the foreseeable issue.\nThat is a huge opportunity for Vaxart. Success with its oral Covid-19 vaccine — which recently received Food and Drug Administration approval to begin phase II clinical trials— would be a huge catalyst for VXRT stock.\nOral Vaccines Have a Practical Application As Well\nCatering to a group that avoids needles is one thing. However, there are also a practical reasons for developing an oral Covid-19 vaccine.\nThe Covid-19 vaccines released to date have had very stringent temperature requirements for transportation and storage, some requiring specialized freezers. That was a challenge at first in parts of North America, but in areas of the world like Africa where temperatures are extreme and infrastructure often lacking, this becomes a big problem. In addition, there have been shortages of syringes and of people trained to administer needles.\nWith an oral vaccination — a pill — these issues go away. Vaxart says its tablets are stable at room temperature, eliminating the challenges with transportation and storage. In addition, there is no special equipment or specialized training needed at clinics where the pills would be distributed.\nBottom Line on VXRT Stock\nWill Vaxart achieve the Holy Grail of a pill-based rDNA vaccine for Covid-19? If the company manages to pull it off, early February’s $23.33 close will likely end up looking like a practice run for VXRT stock. With the vaccine candidate just scheduled to enter phase II clinical trials in the second half of the year, patience is required.\nThisPortfolio GraderB-rated stock is not without risk. Vaccine candidates fail during testing all the time, and underwhelming phase I trial results sank VXRT in February. However, its stock price has stabilized and is trending in the right direction. And in its latest quarter, Vaxart reported it still has$198.9 million in cash and equivalents to keep the lights on while it waits for its oral Covid-19 vaccine to work its way through clinical trials.\nRemember, even if the company doesn’t succeed on the Covid-19 front, the company has other oral vaccine candidates in various stages of development in the pipeline.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5703467,"gmtCreate":1630390210837,"gmtModify":1663233161644,"authorId":3575280267029660,"author":{"id":3575280267029660,"authorId":3575280267029660,"name":"Cindypoonyw","avatar":"https://static.tigerbbs.com/b45818b9b1b80dfeb87d018927a22632","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":818170952,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"}],"langContent":"EN"},{"id":818147821,"gmtCreate":1630389463663,"gmtModify":1676530288939,"author":{"id":"3582125189852786","authorId":"3582125189852786","authorIdStr":"3582125189852786","name":"Kco","avatar":"https://static.tigerbbs.com/7e084f967b4eadfe95c21811f7dac5f3","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3582125189852786"},"htmlText":"Yes!![Miser]&nbsp;","listText":"Yes!![Miser]&nbsp;","text":"Yes!![Miser]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/818147821","repostId":1134243710,"repostType":4,"repost":{"id":"1134243710","pubTimestamp":1630388289,"share":"https://ttm.financial/m/news/1134243710?lang=&edition=fundamental","pubTime":"2021-08-31 13:38","market":"us","language":"en","title":"Is Vaxart Stock Really Worth a Shot?","url":"https://stock-news.laohu8.com/highlight/detail?id=1134243710","media":"InvestorPlace","summary":"If 10% of the population is refusing Covid-19 vaccine shots because they hate needles, that’s good n","content":"<blockquote>\n <b>If 10% of the population is refusing Covid-19 vaccine shots because they hate needles, that’s good news for VXRT stock.</b>\n</blockquote>\n<p>Biotech company&nbsp;<b><a href=\"https://laohu8.com/S/VXRT\">Vaxart, Inc</a></b> is like many others in this space. It’s a clinical-stage company developing recombinant (rDNA) vaccines. It has a focus on Covid-19. And its stock has seen some wild, meme stock-style action in 2021, highlighted by a one-week period that saw VXRT stock spike 161% then plunge back below its starting point.</p>\n<p>What sets Vaxart apart from most of the biotech companies it competes with is syringes. More correctly, a lack of syringes. Instead of a needle, Vaxart’s vaccines are delivered in pill form.</p>\n<p>While VXRT stock experienced massive price fluctuations through the first 5 months of the year, since early May it has been stable with a recovery that is slowing gaining steam. Currently trading near $9, shares are up 40% from the start of the year. Vaxart hasn’t yet landed an approved Covid vaccine. But the Delta variant is proving that vaccination is likely to be an ongoing effort, meaning there is still opportunity there.</p>\n<p>Vaxart has other oral vaccines in the pipeline including versions for norovirus and influenza. So is now the time to hop on the VXRT bandwagon?</p>\n<p><b>There’s Vaccine Hesitancy, But There’s Also Needle Hesitancy</b></p>\n<p>One of the central arguments to the Vaxart approach is that a lot of people strongly dislike needles. They can cause pain and extreme stress.</p>\n<p>Dr. C. Meghan McMurtry is an associate professor of psychology at Canada’s University of Guelph.&nbsp;She wrote in the<i>New York Times</i>: “About one in four adults and two out of three children have some fear of needles, and adults may find their fears too shameful to share. This is a substantial public health problem, because a body of research shows that around one in 10 adults are so afraid of needles that they will delay or avoid vaccinations.”</p>\n<p>Delaying or avoiding vaccination is&nbsp;prolonging the pandemic. Not all vaccine refusers are avoiding the shot because they fear needles. But a substantial number are. And with children under 12 the next big age group that remains to be vaccinated in the U.S., fear of needles is a serious issue.</p>\n<p>Even once the pandemic is under control, it appears that mutations like Delta will mean ongoing&nbsp;booster shots are required. Fear of needles will be a problem for the foreseeable issue.</p>\n<p>That is a huge opportunity for Vaxart. Success with its oral Covid-19 vaccine — which recently&nbsp;received Food and Drug Administration approval to begin phase II clinical trials—&nbsp;would be a&nbsp;huge catalyst for VXRT stock.</p>\n<p><b>Oral Vaccines Have a Practical Application As Well</b></p>\n<p>Catering to a group that avoids needles is one thing. However, there are also a practical reasons for developing an oral Covid-19 vaccine.</p>\n<p>The Covid-19 vaccines released to date have had very stringent temperature requirements for transportation and storage, some requiring specialized freezers. That was a challenge at first in parts of North America, but in areas of the world like Africa where temperatures are extreme and infrastructure often lacking, this becomes a big problem. In addition, there have been&nbsp;shortages of syringes&nbsp;and of people trained to administer needles.</p>\n<p>With an oral vaccination — a pill — these issues go away. Vaxart says its tablets are stable at room temperature, eliminating the challenges with transportation and storage. In addition, there is no special equipment or specialized training needed at clinics where the pills would be distributed.</p>\n<p><b>Bottom Line on VXRT Stock</b></p>\n<p>Will Vaxart achieve the Holy Grail of a pill-based rDNA vaccine for Covid-19? If the company manages to pull it off, early February’s $23.33 close will likely end up looking like a practice run for VXRT stock. With the vaccine candidate just scheduled to enter phase II clinical trials in the second half of the year, patience is required.</p>\n<p>This<i>Portfolio Grader</i>B-rated stock is not without risk. Vaccine candidates fail during testing all the time, and underwhelming phase I trial results sank VXRT in February. However, its stock price has stabilized and is trending in the right direction. And in its latest quarter, Vaxart reported it still has$198.9 million in cash and equivalents&nbsp;to keep the lights on while it waits for its oral Covid-19 vaccine to work its way through clinical trials.</p>\n<p>Remember, even if the company doesn’t succeed on the Covid-19 front, the company has other oral vaccine candidates in various stages of development in the pipeline.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Vaxart Stock Really Worth a Shot?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Vaxart Stock Really Worth a Shot?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-31 13:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/08/is-vaxart-stock-really-worth-a-shot/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>If 10% of the population is refusing Covid-19 vaccine shots because they hate needles, that’s good news for VXRT stock.\n\nBiotech company Vaxart, Inc is like many others in this space. It’s a clinical-...</p>\n\n<a href=\"https://investorplace.com/2021/08/is-vaxart-stock-really-worth-a-shot/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VXRT":"Vaxart, Inc"},"source_url":"https://investorplace.com/2021/08/is-vaxart-stock-really-worth-a-shot/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1134243710","content_text":"If 10% of the population is refusing Covid-19 vaccine shots because they hate needles, that’s good news for VXRT stock.\n\nBiotech company Vaxart, Inc is like many others in this space. It’s a clinical-stage company developing recombinant (rDNA) vaccines. It has a focus on Covid-19. And its stock has seen some wild, meme stock-style action in 2021, highlighted by a one-week period that saw VXRT stock spike 161% then plunge back below its starting point.\nWhat sets Vaxart apart from most of the biotech companies it competes with is syringes. More correctly, a lack of syringes. Instead of a needle, Vaxart’s vaccines are delivered in pill form.\nWhile VXRT stock experienced massive price fluctuations through the first 5 months of the year, since early May it has been stable with a recovery that is slowing gaining steam. Currently trading near $9, shares are up 40% from the start of the year. Vaxart hasn’t yet landed an approved Covid vaccine. But the Delta variant is proving that vaccination is likely to be an ongoing effort, meaning there is still opportunity there.\nVaxart has other oral vaccines in the pipeline including versions for norovirus and influenza. So is now the time to hop on the VXRT bandwagon?\nThere’s Vaccine Hesitancy, But There’s Also Needle Hesitancy\nOne of the central arguments to the Vaxart approach is that a lot of people strongly dislike needles. They can cause pain and extreme stress.\nDr. C. Meghan McMurtry is an associate professor of psychology at Canada’s University of Guelph. She wrote in theNew York Times: “About one in four adults and two out of three children have some fear of needles, and adults may find their fears too shameful to share. This is a substantial public health problem, because a body of research shows that around one in 10 adults are so afraid of needles that they will delay or avoid vaccinations.”\nDelaying or avoiding vaccination is prolonging the pandemic. Not all vaccine refusers are avoiding the shot because they fear needles. But a substantial number are. And with children under 12 the next big age group that remains to be vaccinated in the U.S., fear of needles is a serious issue.\nEven once the pandemic is under control, it appears that mutations like Delta will mean ongoing booster shots are required. Fear of needles will be a problem for the foreseeable issue.\nThat is a huge opportunity for Vaxart. Success with its oral Covid-19 vaccine — which recently received Food and Drug Administration approval to begin phase II clinical trials— would be a huge catalyst for VXRT stock.\nOral Vaccines Have a Practical Application As Well\nCatering to a group that avoids needles is one thing. However, there are also a practical reasons for developing an oral Covid-19 vaccine.\nThe Covid-19 vaccines released to date have had very stringent temperature requirements for transportation and storage, some requiring specialized freezers. That was a challenge at first in parts of North America, but in areas of the world like Africa where temperatures are extreme and infrastructure often lacking, this becomes a big problem. In addition, there have been shortages of syringes and of people trained to administer needles.\nWith an oral vaccination — a pill — these issues go away. Vaxart says its tablets are stable at room temperature, eliminating the challenges with transportation and storage. In addition, there is no special equipment or specialized training needed at clinics where the pills would be distributed.\nBottom Line on VXRT Stock\nWill Vaxart achieve the Holy Grail of a pill-based rDNA vaccine for Covid-19? If the company manages to pull it off, early February’s $23.33 close will likely end up looking like a practice run for VXRT stock. With the vaccine candidate just scheduled to enter phase II clinical trials in the second half of the year, patience is required.\nThisPortfolio GraderB-rated stock is not without risk. Vaccine candidates fail during testing all the time, and underwhelming phase I trial results sank VXRT in February. However, its stock price has stabilized and is trending in the right direction. And in its latest quarter, Vaxart reported it still has$198.9 million in cash and equivalents to keep the lights on while it waits for its oral Covid-19 vaccine to work its way through clinical trials.\nRemember, even if the company doesn’t succeed on the Covid-19 front, the company has other oral vaccine candidates in various stages of development in the pipeline.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5703409,"gmtCreate":1630389489524,"gmtModify":1663233161043,"authorId":3582125189852786,"author":{"id":3582125189852786,"authorId":3582125189852786,"name":"Kco","avatar":"https://static.tigerbbs.com/7e084f967b4eadfe95c21811f7dac5f3","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":818147821,"type":1,"supId":0,"prevId":0,"content":"[Miser][Miser]","text":"[Miser][Miser]","html":"[Miser][Miser]"}],"langContent":"EN"},{"id":818145265,"gmtCreate":1630389301457,"gmtModify":1676530288899,"author":{"id":"3574122255023758","authorId":"3574122255023758","authorIdStr":"3574122255023758","name":"JamesArthur","avatar":"https://static.tigerbbs.com/0230d592c84aee6b78c6136a020bbb52","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3574122255023758"},"htmlText":"Interesting&nbsp;","listText":"Interesting&nbsp;","text":"Interesting","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/818145265","repostId":1134243710,"repostType":4,"repost":{"id":"1134243710","pubTimestamp":1630388289,"share":"https://ttm.financial/m/news/1134243710?lang=&edition=fundamental","pubTime":"2021-08-31 13:38","market":"us","language":"en","title":"Is Vaxart Stock Really Worth a Shot?","url":"https://stock-news.laohu8.com/highlight/detail?id=1134243710","media":"InvestorPlace","summary":"If 10% of the population is refusing Covid-19 vaccine shots because they hate needles, that’s good n","content":"<blockquote>\n <b>If 10% of the population is refusing Covid-19 vaccine shots because they hate needles, that’s good news for VXRT stock.</b>\n</blockquote>\n<p>Biotech company&nbsp;<b><a href=\"https://laohu8.com/S/VXRT\">Vaxart, Inc</a></b> is like many others in this space. It’s a clinical-stage company developing recombinant (rDNA) vaccines. It has a focus on Covid-19. And its stock has seen some wild, meme stock-style action in 2021, highlighted by a one-week period that saw VXRT stock spike 161% then plunge back below its starting point.</p>\n<p>What sets Vaxart apart from most of the biotech companies it competes with is syringes. More correctly, a lack of syringes. Instead of a needle, Vaxart’s vaccines are delivered in pill form.</p>\n<p>While VXRT stock experienced massive price fluctuations through the first 5 months of the year, since early May it has been stable with a recovery that is slowing gaining steam. Currently trading near $9, shares are up 40% from the start of the year. Vaxart hasn’t yet landed an approved Covid vaccine. But the Delta variant is proving that vaccination is likely to be an ongoing effort, meaning there is still opportunity there.</p>\n<p>Vaxart has other oral vaccines in the pipeline including versions for norovirus and influenza. So is now the time to hop on the VXRT bandwagon?</p>\n<p><b>There’s Vaccine Hesitancy, But There’s Also Needle Hesitancy</b></p>\n<p>One of the central arguments to the Vaxart approach is that a lot of people strongly dislike needles. They can cause pain and extreme stress.</p>\n<p>Dr. C. Meghan McMurtry is an associate professor of psychology at Canada’s University of Guelph.&nbsp;She wrote in the<i>New York Times</i>: “About one in four adults and two out of three children have some fear of needles, and adults may find their fears too shameful to share. This is a substantial public health problem, because a body of research shows that around one in 10 adults are so afraid of needles that they will delay or avoid vaccinations.”</p>\n<p>Delaying or avoiding vaccination is&nbsp;prolonging the pandemic. Not all vaccine refusers are avoiding the shot because they fear needles. But a substantial number are. And with children under 12 the next big age group that remains to be vaccinated in the U.S., fear of needles is a serious issue.</p>\n<p>Even once the pandemic is under control, it appears that mutations like Delta will mean ongoing&nbsp;booster shots are required. Fear of needles will be a problem for the foreseeable issue.</p>\n<p>That is a huge opportunity for Vaxart. Success with its oral Covid-19 vaccine — which recently&nbsp;received Food and Drug Administration approval to begin phase II clinical trials—&nbsp;would be a&nbsp;huge catalyst for VXRT stock.</p>\n<p><b>Oral Vaccines Have a Practical Application As Well</b></p>\n<p>Catering to a group that avoids needles is one thing. However, there are also a practical reasons for developing an oral Covid-19 vaccine.</p>\n<p>The Covid-19 vaccines released to date have had very stringent temperature requirements for transportation and storage, some requiring specialized freezers. That was a challenge at first in parts of North America, but in areas of the world like Africa where temperatures are extreme and infrastructure often lacking, this becomes a big problem. In addition, there have been&nbsp;shortages of syringes&nbsp;and of people trained to administer needles.</p>\n<p>With an oral vaccination — a pill — these issues go away. Vaxart says its tablets are stable at room temperature, eliminating the challenges with transportation and storage. In addition, there is no special equipment or specialized training needed at clinics where the pills would be distributed.</p>\n<p><b>Bottom Line on VXRT Stock</b></p>\n<p>Will Vaxart achieve the Holy Grail of a pill-based rDNA vaccine for Covid-19? If the company manages to pull it off, early February’s $23.33 close will likely end up looking like a practice run for VXRT stock. With the vaccine candidate just scheduled to enter phase II clinical trials in the second half of the year, patience is required.</p>\n<p>This<i>Portfolio Grader</i>B-rated stock is not without risk. Vaccine candidates fail during testing all the time, and underwhelming phase I trial results sank VXRT in February. However, its stock price has stabilized and is trending in the right direction. And in its latest quarter, Vaxart reported it still has$198.9 million in cash and equivalents&nbsp;to keep the lights on while it waits for its oral Covid-19 vaccine to work its way through clinical trials.</p>\n<p>Remember, even if the company doesn’t succeed on the Covid-19 front, the company has other oral vaccine candidates in various stages of development in the pipeline.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Vaxart Stock Really Worth a Shot?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Vaxart Stock Really Worth a Shot?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-31 13:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/08/is-vaxart-stock-really-worth-a-shot/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>If 10% of the population is refusing Covid-19 vaccine shots because they hate needles, that’s good news for VXRT stock.\n\nBiotech company Vaxart, Inc is like many others in this space. It’s a clinical-...</p>\n\n<a href=\"https://investorplace.com/2021/08/is-vaxart-stock-really-worth-a-shot/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VXRT":"Vaxart, Inc"},"source_url":"https://investorplace.com/2021/08/is-vaxart-stock-really-worth-a-shot/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1134243710","content_text":"If 10% of the population is refusing Covid-19 vaccine shots because they hate needles, that’s good news for VXRT stock.\n\nBiotech company Vaxart, Inc is like many others in this space. It’s a clinical-stage company developing recombinant (rDNA) vaccines. It has a focus on Covid-19. And its stock has seen some wild, meme stock-style action in 2021, highlighted by a one-week period that saw VXRT stock spike 161% then plunge back below its starting point.\nWhat sets Vaxart apart from most of the biotech companies it competes with is syringes. More correctly, a lack of syringes. Instead of a needle, Vaxart’s vaccines are delivered in pill form.\nWhile VXRT stock experienced massive price fluctuations through the first 5 months of the year, since early May it has been stable with a recovery that is slowing gaining steam. Currently trading near $9, shares are up 40% from the start of the year. Vaxart hasn’t yet landed an approved Covid vaccine. But the Delta variant is proving that vaccination is likely to be an ongoing effort, meaning there is still opportunity there.\nVaxart has other oral vaccines in the pipeline including versions for norovirus and influenza. So is now the time to hop on the VXRT bandwagon?\nThere’s Vaccine Hesitancy, But There’s Also Needle Hesitancy\nOne of the central arguments to the Vaxart approach is that a lot of people strongly dislike needles. They can cause pain and extreme stress.\nDr. C. Meghan McMurtry is an associate professor of psychology at Canada’s University of Guelph. She wrote in theNew York Times: “About one in four adults and two out of three children have some fear of needles, and adults may find their fears too shameful to share. This is a substantial public health problem, because a body of research shows that around one in 10 adults are so afraid of needles that they will delay or avoid vaccinations.”\nDelaying or avoiding vaccination is prolonging the pandemic. Not all vaccine refusers are avoiding the shot because they fear needles. But a substantial number are. And with children under 12 the next big age group that remains to be vaccinated in the U.S., fear of needles is a serious issue.\nEven once the pandemic is under control, it appears that mutations like Delta will mean ongoing booster shots are required. Fear of needles will be a problem for the foreseeable issue.\nThat is a huge opportunity for Vaxart. Success with its oral Covid-19 vaccine — which recently received Food and Drug Administration approval to begin phase II clinical trials— would be a huge catalyst for VXRT stock.\nOral Vaccines Have a Practical Application As Well\nCatering to a group that avoids needles is one thing. However, there are also a practical reasons for developing an oral Covid-19 vaccine.\nThe Covid-19 vaccines released to date have had very stringent temperature requirements for transportation and storage, some requiring specialized freezers. That was a challenge at first in parts of North America, but in areas of the world like Africa where temperatures are extreme and infrastructure often lacking, this becomes a big problem. In addition, there have been shortages of syringes and of people trained to administer needles.\nWith an oral vaccination — a pill — these issues go away. Vaxart says its tablets are stable at room temperature, eliminating the challenges with transportation and storage. In addition, there is no special equipment or specialized training needed at clinics where the pills would be distributed.\nBottom Line on VXRT Stock\nWill Vaxart achieve the Holy Grail of a pill-based rDNA vaccine for Covid-19? If the company manages to pull it off, early February’s $23.33 close will likely end up looking like a practice run for VXRT stock. With the vaccine candidate just scheduled to enter phase II clinical trials in the second half of the year, patience is required.\nThisPortfolio GraderB-rated stock is not without risk. Vaccine candidates fail during testing all the time, and underwhelming phase I trial results sank VXRT in February. However, its stock price has stabilized and is trending in the right direction. And in its latest quarter, Vaxart reported it still has$198.9 million in cash and equivalents to keep the lights on while it waits for its oral Covid-19 vaccine to work its way through clinical trials.\nRemember, even if the company doesn’t succeed on the Covid-19 front, the company has other oral vaccine candidates in various stages of development in the pipeline.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5703412,"gmtCreate":1630389511017,"gmtModify":1663233161542,"authorId":3581648699031335,"author":{"id":3581648699031335,"authorId":3581648699031335,"name":"HeatWave","avatar":"https://static.tigerbbs.com/df15a10254b322279c673072699eb4cf","vip":1,"currentWearingBadge":{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1100},"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":818145265,"type":1,"supId":0,"prevId":0,"content":"<u>yes</u>","text":"<u>yes</u>","html":"<u>yes</u>"}],"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":53,"commentSize":5,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}